Phaseline

Targets › CES1

CES1 (Liver carboxylesterase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology.

Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. (UniProt, P23141)

Open in Phaseline: the race on CES1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterCarboxylesterase-expressing Allogeneic Neural Stem Cells
Genetically modified neural stem cells expressing carboxylesterase (CE) to enhance tumor s
CES1Phase 1Recurrent Anaplastic Astrocytoma–

Conditions

Recurrent Anaplastic Astrocytoma (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.